Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 4/20 | 0.42 |
| ▸ | RXRB | P28702 | 3/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522454 | 0.91 | PARP10 (0.50) | MAPK14GAA | |
| SCHEMBL3520099 | 0.90 | HDAC6 (0.45) | — | |
| SCHEMBL3524455 | 0.89 | FGFR1 (0.50) | POLBMEN1KMT2AHPGD | |
| SCHEMBL3526646 | 0.84 | MAOB (0.43) | MAPK14MEN1KMT2AHPGD | |
| SCHEMBL5267895 | 0.83 | SIGMAR1 (0.45) | MEN1KMT2AHPGD | |
| SCHEMBL3525381 | 0.83 | ALDH1A1 (0.51) | MEN1KMT2AHPGDGAA | |
| Hydrochloric Acid SCHEMBL3521848 | 0.83 | SIGMAR1 (0.44) | MEN1KMT2AHPGD | |
| SCHEMBL3521536 | 0.82 | MAPT (0.39) | POLBMAPK14MEN1KMT2A | |
| SCHEMBL3522032 | 0.82 | MAOB (0.48) | MAPK14 | |
| SCHEMBL3520672 | 0.82 | MAPK14 (0.51) | NR4A1NR4A2NR4A3SRD5A2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1753731-A2 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS | Pharmacia Corporation (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
| WO-2004087677-A2 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | NR4A1 2532/4885NR4A2 2750/4885NR4A3 3220/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | NR4A1 2568/4885NR4A2 3054/4885NR4A3 3532/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | NR4A1 2532/4885NR4A2 2750/4885NR4A3 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.